iRhythm logo

iRhythm(NASDAQ) IRTC

Market Cap$4.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+366%
5 Year+78%
1 Year-33%
1 Month+9%
Premium Feature
Moneyball Superscore
70/100
$121.24
+1.34%
+1.60Today
After hours$121.25+$0.01 (+0.01%)
iRhythm last closing stock price
MetricPriceDate
Last closeUSD 121.272026-10-23
iRhythm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.61%USD 108.662026-10-16
1 month+8.52%USD 111.752026-09-23
3 month+11.05%USD 109.202026-07-24
Year to date-31.66%USD 177.442025-12-31
1 year-33.47%USD 182.272025-10-23
3 year+51.06%USD 80.282023-10-24
5 year+78.34%USD 68.002021-10-22
Since inception+365.53%USD 26.052016-10-20

iRhythm Financials at a Glance

Market Cap

$4.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$825.34M

Net Income (TTM)

-$13.95M

EPS (TTM)

-$0.43

P/E Ratio

-278.91

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$121.24

Volume

456,765.346

Open

$119.35

Previous Close

$121.27

Daily Range

$117.67 - $122.50

52-Week Range

$100.70 - $212.00

Estimated Earnings Date

Nov 5, 2026

IRTC: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About iRhythm

iRhythm Holdings, Inc. NASDAQ:IRTC tracks heartbeats to find irregular rhythms. Patients wear a small patch that records their heart data. Computers in the cloud analyze this data for doctors.

Who Pays for Services?

  • Contracted Third-Party Payors: Insurance companies with pre-negotiated rates for monitoring services; accounts for 52% of revenue.
  • Centers for Medicare & Medicaid Services: Government-funded health coverage for elderly and disabled patients; represents 26% of revenue.
  • Healthcare Institutions: Direct sales of monitoring services to hospitals and private clinics; makes up 16% of revenue.
  • Non-Contracted Third-Party Payors: Insurance providers without formal pricing agreements; contributes 6% of revenue.

New Tech and New Deals

  • Acquired a technology license from BioIS on Aug. 30, 2024, to develop blood pressure and sleep apnea features.
  • Terminated a development partnership with Verily Life Sciences in August 2025.
  • Settled long-standing patent litigation with Baxter and its subsidiaries for $50 million on July 31, 2026.
  • Entered a definitive agreement on Aug. 5, 2026, to acquire VitalConnect for $237.5 million in cash and $50 million in stock.

What Makes the Tech Unique?

The company uses a cloud-based platform to curate over 3 billion hours of heartbeat data for medical reports. Operating through independent diagnostic testing facilities allows the firm to provide full-service monitoring directly to clinicians.

Performance by the Numbers

  • Net revenue rose 23% year over year to $423.6 million for the six-month period ended June 30, 2026.
  • Gross profit reached $304.6 million for the six-month period ended June 30, 2026, up 26% year over year.
  • Net loss was $14.3 million for the six-month period ended June 30, 2026, down 68% year over year.
  • Cash provided by operating activities was $24.9 million for the six-month period ended June 30, 2026.

Bottom Line

iRhythm has transitioned from a single-product provider to an integrated digital health platform with a clinical data set. The company is currently expanding its diagnostic reach through acquisitions and licenses for new biosensor technologies.

AI Generated • Aug 7, 2026

Industry

Healthcare Equipment and Supplies

Employees

2,400

CEO

Quentin S. Blackford, CPA

Headquarters

San Francisco, CA 94103, US

IRTC Financials

Key Financial Metrics (TTM)

Gross Margin

71.45%

Operating Margin

-1.17%

Net Income Margin

-1.69%

Return on Equity

-8.97%

Return on Capital

-4.16%

Return on Assets

-1.28%

Earnings Yield

-0.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

32.96M

Volume

456.77K

Avg. Volume

568.62K

Financials (TTM)

Gross Profit

$589.74M

Operating Income

-$9.63M

EBITDA

$26.86M

Operating Cash Flow

$86.00M

Capital Expenditure

-$47.02M

Free Cash Flow

$38.98M

Cash & ST Invst.

$591.27M

Total Debt

$727.35M

iRhythm Performance Analysis

iRhythm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 410,921,00027.3%
20232023-12-31USD 492,681,00019.9%
20242024-12-31USD 591,839,00020.1%
20252025-12-31USD 747,138,00026.2%
iRhythm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.3%
Q42025-12-318.3%
Q12026-03-31-4.5%
Q22026-06-3012.4%
iRhythm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.8812.4%
20232023-12-31USD -4.044.1%
20242024-12-31USD -3.63-10.2%
20252025-12-31USD -1.39-61.7%
iRhythm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3063.6%
Q42025-12-31206.3%
Q12026-03-31-352.9%
Q22026-06-3097.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$224.17M

+20.1%

Gross Profit

$163.21M

+22.8%

Gross Margin

72.80%

N/A

Market Cap

$4.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.67M

N/A

Employees

2,400

N/A

Net Income

-$381.00K

+97.3%

EBITDA

$9.67M

+310.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$591.27M

+8.4%

Total Debt

$727.35M

-1.0%

Accounts Receivable

$84.27M

+2.6%

Inventory

$22.51M

+22.4%

Long Term Debt

$710.44M

-1.1%

Short Term Debt

$18.42M

+12.6%

Return on Assets

-1.28%

N/A

Return on Invested Capital

-1.07%

N/A

Free Cash Flow

$37.52M

+117.0%

Operating Cash Flow

$51.08M

+84.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LIVNLivaNova PLC
$80.90-0.46%
ATRCAtriCure, Inc.
$58.97-0.56%
KMTSKestra Medical Technologies, Ltd.
$28.76+1.55%
BEATHeartBeam, Inc.
$0.39-1.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About IRTC

What is the current price of iRhythm?

iRhythm is trading at $121.27 per share.

What is the 52-week range for iRhythm?

Over the past 52 weeks, iRhythm has traded between $100.70 and $212.00.

How much debt does iRhythm have?

As of the most recent reporting period, iRhythm reported total debt of $727.35M.

How much cash does iRhythm have on hand?

iRhythm reported $246.68M in cash and cash equivalents in its most recent financial results.

What is iRhythm’s dividend yield?

iRhythm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.